Abstract:Drug repositioning identifies novel therapeutic potentials for existing drugs and is considered an attractive approach due to the opportunity for reduced development timelines and overall costs. Prior computational methods usually learned a drug's representation from an entire graph of drug-disease associations. Therefore, the representation of learned drugs representation are static and agnostic to various diseases. However, for different diseases, a drug's mechanism of actions (MoAs) are different. The relevant context information should be differentiated for the same drug to target different diseases. Computational methods are thus required to learn different representations corresponding to different drug-disease associations for the given drug. In view of this, we propose an end-to-end partner-specific drug repositioning approach based on graph convolutional network, named PSGCN. PSGCN firstly extracts specific context information around drug-disease pairs from an entire graph of drug-disease associations. Then, it implements a graph convolutional network on the extracted graph to learn partner-specific graph representation. As the different layers of graph convolutional network contribute differently to the representation of the partner-specific graph, we design a layer self-attention mechanism to capture multi-scale layer information. Finally, PSGCN utilizes sortpool strategy to obtain the partner-specific graph embedding and formulates a drug-disease association prediction as a graph classification task. A fully-connected module is established to classify the partner-specific graph representations. The experiments on three benchmark datasets prove that the representation learning of partner-specific graph can lead to superior performances over state-of-the-art methods. In particular, case studies on small cell lung cancer and breast carcinoma confirmed that PSGCN is able to retrieve more actual drug-disease associations in the top prediction results. Moreover, in comparison with other static approaches, PSGCN can partly distinguish the different disease context information for the given drug.

Enhancing Drug Repositioning through Local Interactive Learning with Bilinear Attention Networks

A weighted bilinear neural collaborative filtering approach for drug repositioning

Drug repositioning based on the heterogeneous information fusion graph convolutional network

Drug repositioning based on weighted local information augmented graph neural network

Drug Repositioning by Collaborative Learning Based on Graph Convolutional Inductive Network

Drug repositioning with adaptive graph convolutional networks

Knowledge Graph Convolutional Network with Heuristic Search for Drug Repositioning

DRGCL: Drug Repositioning Via Semantic-enriched Graph Contrastive Learning.

Drug Repositioning Method Based on Deep Neural Network

Drug Repositioning Based on the Enhanced Message Passing and Hypergraph Convolutional Networks

Prediction of drug–disease associations based on reinforcement symmetric metric learning and graph convolution network

Drug Repositioning Via Multi-view Representation Learning with Heterogeneous Graph Neural Network

An Enhanced LRMC Method for Drug Repositioning Via GCN-based HIN Embedding

Attention Transfer in Heterogeneous Networks Fusion for Drug Repositioning

Partner-Specific Drug Repositioning Approach Based on Graph Convolutional Network

deepDR: a network-based deep learning approach to in silico drug repositioning

Boosting drug-disease association prediction for drug repositioning via dual-feature extraction and cross-dual-domain decoding

Predicting drug-disease associations by network embedding and biomedical data integration.

DRONet: effectiveness-driven drug repositioning framework using network embedding and ranking learning

Drug Repositioning by Multi-Aspect Heterogeneous Graph Contrastive Learning and Positive-Fusion Negative Sampling Strategy

Regulation-aware graph learning for drug repositioning over heterogeneous biological network